A team of UK rheumatologists has urged clinicians to not delay treatment with methotrexate in rheumatoid arthritis because of fears over lung injury. In fact, use of methotrexate in a treat-to-target approach in patients with progressive disease may prevent the development of interstitial lung disease (ILD) developing, they conclude. Dr Elena Nikiphorou, a clinical researcher ...
New thinking on methotrexate: don’t delay treatment due to fears of ILD
By Emma Wilkinson
12 Nov 2019